| | EMEA Pushes Suspension of RimonabantEuropean regulators Oct. 23 recommended suspending the obesity drug rimonabant from the marketplace, citing risks of psychiatric disorders. PII: S1558-0164(08)70400-0 doi:10.1016/S1558-0164(08)70400-0 © 2008 Elsevier Inc. All rights reserved. | |
|
|